Genocea Biosciences, a Cambridge, MA-based firm that specializes in rapidly discovering potential vaccines, said today it has named Chip Clark as its new chief executive. Clark, who played a key role in the firm’s recent $35 million Series B financing, was previously the company’s chief business officer, a job he took in August 2010. He has been in the drug industry for more than 20 years, and prior to joining the company he was chief business officer of Vanda Pharmaceuticals in Rockville, MD. Staph Bakali, Genocea’s previous CEO, ended his stint as the firm’s chief executive in September.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
